# Journal of Visualized Experiments ASSAYING PROTEASOMAL DEGRADATION IN A CELL-FREE SYSTEM IN PLANTS --Manuscript Draft--

Manuscript Number:	JoVE51293R2
Full Title:	ASSAYING PROTEASOMAL DEGRADATION IN A CELL-FREE SYSTEM IN PLANTS
Article Type:	Methods Article - JoVE Produced Video
Keywords:	Ubiquitin/proteasome system; 26S proteasome; protein degradation; proteasome inhibitor; Western blotting; plant genetic transformation
Manuscript Classifications:	4.12.776.765: Plant Proteins; 4.13.444.735.635: RNA, Plant; 4.20.215.784: Plant Preparations; 4.20.215.784.500: Plant Extracts
Corresponding Author:	Maria Elena Garcia Stony Brook university Stony Brook, NY UNITED STATES
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	biomelena@hotmail.com
Corresponding Author's Institution:	Stony Brook university
Corresponding Author's Secondary Institution:	
First Author:	Maria Elena Garcia
First Author Secondary Information:	
Other Authors:	Adi Zaltsman
	Vitaly Citovsky
Order of Authors Secondary Information:	
Abstract:	The ubiquitin-proteasome pathway for protein degradation has emerged as one of the most important mechanisms for regulation of a wide spectrum of cellular functions in virtually all eukaryotic organisms. Specifically, in plants, the ubiquitin/26S proteasome system (UPS) regulates protein degradation and contributes significantly to development of a wide range of processes, including immune response, development and programmed cell death. Moreover, increasing evidence suggests that numerous plant pathogens, such as Agrobacterium, exploit the host UPS for efficient infection, emphasizing the importance of UPS in plant-pathogen interactions.  The substrate specificity of UPS is achieved by the E3 ubiquitin ligase that acts in concert with the E1 and E2 ligases to recognize and mark specific protein molecules destined for degradation by attaching to them chains of ubiquitin molecules. One class of the E3 ligases is the SCF (Skp1/Cullin/F-box protein) complex, which specifically recognizes the UPS substrates and targets them for ubiquitination via its F-box protein component. To investigate a potential role of UPS in a biological process of interest, it is important to devise a simple and reliable assay for UPS-mediated protein degradation. Here, we describe one such assay using a plant cell-free system. This assay can be adapted for studies of the roles of regulated protein degradation in diverse cellular processes, with a special focus on the F-box protein-substrate interactions.
Author Comments:	No comments
Additional Information:	
Question	Response

## ASSAYING PROTEASOMAL DEGRADATION IN A CELL-FREE SYSTEM IN PLANTS

Elena García-Cano, Adi Zaltsman and Vitaly Citovsky
Department of Biochemistry and Cell Biology, Stony Brook University, Stony
Brook, NY 11794-5215, USA

Correspondence to: Elena Garcia-Cano at e.garcia-cano@stonybrook.edu

#### **KEYWORDS**

Ubiquitin/proteasome system; 26S proteasome; protein degradation; proteasome inhibitor; western blotting; plant genetic transformation

#### SHORT ABSTRACT

Targeted protein degradation represents a major regulatory mechanism for cell function. It occurs via a conserved ubiquitin-proteasome pathway, which attaches polyubiquitin chains to the target protein that then serve as molecular "tags" for the 26S proteasome. Here, we describe a simple and reliable cell-free assay for proteasomal degradation of proteins.

#### LONG ABSTRACT

The ubiquitin-proteasome pathway for protein degradation has emerged as one of the most important mechanisms for regulation of a wide spectrum of cellular functions in virtually all eukaryotic organisms. Specifically, in plants, the ubiquitin/26S proteasome system (UPS) regulates protein degradation and contributes significantly to development of a wide range of processes, including immune response, development and programmed cell death. Moreover, increasing evidence suggests that numerous plant pathogens, such as Agrobacterium, exploit the host UPS for efficient infection, emphasizing the importance of UPS in plant-pathogen interactions.

The substrate specificity of UPS is achieved by the E3 ubiquitin ligase that acts in concert with the E1 and E2 ligases to recognize and mark specific protein molecules destined for degradation by attaching to them chains of ubiquitin molecules. One class of the E3 ligases is the SCF (Skp1/Cullin/F-box protein) complex, which specifically recognizes the UPS substrates and targets them for ubiquitination via its F-box protein component. To investigate a potential role of UPS in a biological process of interest, it is important to devise a simple and reliable assay for UPS-mediated protein degradation. Here, we describe one such assay using a plant cell-free system. This assay can be adapted for studies of the roles of regulated protein degradation in diverse cellular processes, with a special focus on the F-box protein-substrate interactions.

## INTRODUCTION

The ubiquitin/26S proteasome pathway is emerging as a widespread mechanism for control of diverse biological reactions, including transcriptional regulation, cell-cycle progression and signal transduction, receptor down-regulation or endocytosis, among others processes<sup>1-4</sup>. In this pathway, the target protein is tagged by ubiquitin residues which are first attached via a thiolester bond to ubiquitin-activating enzyme E1 and then translocated to a cysteine amino acid residue of ubiquitin-conjugation enzyme E2; finally, E2 interacts with ubiquitin ligase E3, ultimately resulting in polyubiquitination of the protein substrate. Ultimately, the polyubiquitinated proteins

are recognized and degraded by the 26S proteasome. In this mechanism, the E3 enzyme specifies the substrate and acts as the key regulatory component of the ubiquitin/26S proteasome system (UPS). E3 ligases can act independently, such as RING domain ligases, or as part of a multisubunit SCF (Skp1/Cullin/F-box protein) complex, such as F-box domain ligases. SCF-mediated proteasomal degradation pathways are involved in regulation of transcription, cell cycle, signal transduction<sup>5-10</sup> and many other major cellular functions.

Besides these critical roles in regulation of cellular processes, UPS takes the central stage in many plant-pathogen interactions. For example, increasing evidence suggests that several plant pathogens, including Agrobacterium tumefaciens, rely on the host UPS for to facilitate the infection process<sup>11</sup>. Agrobacterium elicits neoplastic growths on plants, which represent its natural hosts, and it can also transform a wide range of other eukaryotes, from fungi [1,2] to human cells 12-13. During its infection, Agrobacterium exports a DNA element (T-DNA) and several virulence (Vir) proteins into the host cell <sup>12-13</sup>. One of these proteins is VirF, the first F-box protein found to be encoded by a prokaryotic genome<sup>14</sup>. As part of the SCF ubiquitin ligase complex, VirF, and its functional host homolog VBF<sup>15</sup>, facilitate Agrobacterium infection via the UPS-mediated protein degradation, which presumably facilitates uncoating of the invading bacterial T-DNA from its accompanying bacterial and host proteins, VirE2 and VIP1, respectively 16-17. Interestingly, many F-box proteins, including VirF, are intrinsically unstable due to their own proteolysis, which is mediated by autoubiquitination activity 18-19 or by other E3 ligases for which F-box proteins may serve as substrates<sup>20-23</sup>.

When studying biochemical activities of F-box proteins, other ubiquitin ligases, and/or their substrates, it would be very useful to employ a simple and reliable assay for proteasomal degradation. Here we describe one such protocol for analyzing protein stability in a cell-free system. In this assay, the stability of the UPS substrate is analyzed in the presence or absence of one of the essential components of the proteasomal degradation pathway, such as an F-box protein, in a cell-free system. Generally, we express the tested protein(s) in plant tissues, prepare cell-free extracts from these tissues and monitor the amounts of the protein(s) of interest by western blotting. The UPS-dependent mechanism of protein degradation is demonstrated by inclusion of specific proteasomal inhibitors and/or using coexpression of dominant-negative form of an SCF component, Cullin. Whereas we illustrate this assay using proteasomal degradation of the Arabidopsis VIP1<sup>17</sup> protein by the F-box protein VBF<sup>15</sup>, it may be employed to investigate the stability of any other proteasomal substrates.

## **PROTOCOL**

## 1.1 Protein expression

## 1.2 Choice of expression system

Select the system, i.e., vectors and vector delivery method, best suited for expression of the protein of interest in the specific model organism/cell. Note that our assay requires expression of the tested proteins in easily detectible amounts, which is best achieved by transient transformation of large numbers of cells. In plants, for example, this is best accomplished using binary plasmids as expression vectors and Agrobacterium as delivery system.

## 1.3 Construction of binary expression vectors

Clone the coding sequence(s) of the protein(s) of interest into an expression vector either alone or in translational fusion to an epitope tag. Use vectors suitable for the chosen expression system and standard molecular biology procedures for gene cloning. For Agrobacterium-mediated gene delivery, employ binary vectors and introduce them, also using standard protocols, into an Agrobacterium strain, such as EHA105, for subsequent inoculation of plant tissues.

# 1.4 Choice of plant species

Select the plant species in which the protein(s) of interest will be expressed. Note that, while any plant species susceptible to Agrobacterium-mediated genetic transformation can be used, our plant species of choice is *Nicotiana benthamiana*, which is easily grown, highly susceptible to Agrobacterium, and has large leaves which are easily inoculated.

# 1.5 Plant growth

- 1.5.1 Grow one plant for 4 to 6 weeks in a pot with Pro-Mix BX in a pot (20 cm x 20 cm x 20 cm) under environmentally-controlled conditions (e.g., growth chamber) of long day (i.e., 16 h of 130-150  $\mu$ E m-2 s-1 light at 23°C and 8 h dark at 20°C) and 40-65% relative humidity.
- 1.5.2 Fertilize occasionally with commercially available products per manufacturer's instructions. Once the plant is grown, select leaves with the size of 50 mm  $\times$  70 mm or larger (these length measurements do not include the petiole) for Agrobacterium inoculation.

#### 1.6 Inoculation with Agrobacterium

- 1.6.1 Grow Agrobacterium strain harboring the binary construct expressing the tested protein(s) from step 1.3 overnight at 28°C in YEP medium (1% peptone, 1% yeast extract, and 0.5% NaCl) supplemented with appropriate antibiotics (e.g., 100 mg/L streptomycin and 10 mg/L rifampicin for pPZP-RSC2-based vectors<sup>24-25</sup>).
- 1.6.2 Centrifuge the cells, resuspended to  $OD_{600}$  =0.5 in infiltration buffer [10 mM MgCl<sub>2</sub>, 10 mM MES (pH 5.6), 100  $\mu$ M acetosyringone], and incubate for 2 h at room temperature. Infiltrate the culture into the abaxial side of a leaf, using a 1-mL needleless syringe; note that the leaves are inoculated in situ, while is attached to the plant.
- 1.6.3 After infiltration, grow the plant for 72 h under the light regime of 16 h 130-150  $\mu$ E m-2 s-1 light at 23°C/8 h dark at 20°C before harvesting.

#### 1.7 Application of proteasomal inhibitors

To support the notion that the tested protein(s) is degraded via a proteasomal pathway, use specific proteasomal inhibitors MG132 and lactacystin  $^{28\text{-}29}$ , which should reduce or even block degradation. Four hours before harvesting (see Step 2.1), infiltrate the Agrobacterium-inoculated leaf areas with 10  $\mu M$  MG132 (EMD Millipore) or 10  $\mu M$  lactacystin (Sigma-Aldrich) or mock-treat the leaf with the respective solvents, i.e., 0.1% DMSO or distilled water.

# 2. Preparation of cell-free extracts

## 2.1 Leaf harvesting

Harvest the inoculated areas of the leaf, usually ca. 200-400 mg of fresh weight, and grind them into fine powder in liquid nitrogen. Alternatively, bead-beat the tissues, using any bead-beater (e.g., Biospec) or a dental amalgamator (e.g., TPC Advanced Technologies) directly in the degradation buffer (see Step 2.2).

#### 2.2 Protein extraction

Prepare total protein extract by placing the ground tissue into 500  $\mu$ L of degradation buffer [50mM Tris-HCL (pH 7.5), 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 5 mM DTT, 5 mM adenosine 5'-triphosphate, and 1x protease inhibitor cocktail (Sigma-Aldrich)]. Note that the protease inhibitor cocktail mainly affects serine, cysteine, aspartic, and metalloproteases and does not interfere with the 26S protease. Clarify the extract by two sequential centrifugations at 12,000 x g for 5 min.

## 2.3 Protein degradation reaction

Transfer equal volumes of extracts, usually 20  $\mu$ L, to microfuge tubes and incubate them at room temperature for increasing periods of time. Typically, sample time zero, and 5, 10, 15, 20, and 30 min time points. Stop reactions by boiling in SDS gelsample buffer, and analyze them by western blotting.

# 3. Detecting protein degradation by immunoblotting

# 3.1 Gel electrophoresis

- 3.1.1 Resolve the protein samples by SDS-polyacrylamide gel electrophoresis and electrotransfer the resolved proteins to a nitrocellulose membrane according to the standard protocol<sup>30</sup>.
- 3.1.2 Determine protein concentration using the Bradford method, and load 50-80 µg of total protein per lane. Make sure that all samples are loaded equally. For loading controls, compare intensities of a ubiquitous protein species, such as putative RuBisCo large chains which migrate as a major band with a relative electrophoretic mobility of around 50 kDa; they can be detected on Coomassie bluestained gels or on Ponceau S- or fluorescent SYPRO Ruby-stained nitrocellulose membranes.

#### 3.2 Blocking

Block the membrane with 5% skim milk in TBST (10 mM Tris-HCl, 140 mM NaCl, 0.05% Tween 20, pH 7.4) for 1 h at room temperature.

# 3.3 Primary antibody

Dilute primary anti-epitope antibody in 1% skim milk in TBST to the concentration recommended by the manufacturer and incubate with the blocked membrane for 1 h at room temperature or for overnight at 4°C with gentle agitation.

# 3.4 Rinsing

Rinse the membrane is rinsed in 20 ml TBST for 15 min once, and twice for 5 min at room temperature with gentle agitation.

## 3.5 Secondary antibody

Dilute secondary antibody (e.g., anti-rabbit IgG) conjugated with horse radish peroxidase (HRP) in 1% skim milk in TBST as recommended by the manufacturer and incubate with the membrane for 1 h at room temperature with gentle agitation.

#### 3.6 Detection

Rinse the membrane again as described in Step 3.4. After the final rinse in TBST, visualize the proteins of interest with an HRP chemiluminescent substrate, most commonly using an ECL kit.

## REPRESENTATIVE RESULTS

Figure 1, adapted from Zaltsman et al. <sup>17</sup>, illustrates representative experiments for detection of proteasomal degradation in a cell-free system. Specifically, we demonstrate destabilization of a plant defense-related protein VIP1 by the VBF F-box protein via the SCF Pathway in *N. benthamiana*. Arabidopsis VBF and HA-tagged VIP1 (HA-VIP1) proteins were transiently coexpressed, and HA-VIP1 content protein within extracts of the expressing leaves was analyzed by western blotting. This analysis demonstrated that VIP1 amounts were reduced to a significant degree when coexpressed with VBF, but remained relatively stable in the absence of VBF coexpression (Figure 1A). Note that a slight reduction in the VIP1 content without VBF may be due to the low level of the endogenous tobacco VBF activity. The proteasomal degradation mechanism of VIP1 destabilization by VBF was inferred from its inhibition by MG132 (Figure 1A). Quantification of the results in Figure 1A demonstrated almost complete (≥90±5%) VIP1 by VBF, which was blocked by MG132 (Figure 1B). Note that slightly higher levels of VIP1 in the presence of MG132 most likely are explained by inhibition of the endogenous VBF activity<sup>17</sup>.

## Figure Legend

**Figure 1**. VBF promotes proteasomal degradation of VIP1. HA-VIP1 was expressed alone or coexpressed with VBF in *N. benthamiana* leaves. The resulting protein extracts were incubated for the indicated time periods and analyzed by western blotting using anti-HA antibodies. The putative RuBisCo large chain was used as loading control (A). Quantified western blot signal was expressed as percent of the signal obtained in the absence of VBF at the start of the incubation period. The data represent average values of three independent experiments with indicated standard deviations (B). This Figure was adapted from Zaltsman et al.<sup>17</sup>

#### DISCUSSION

This assay relies on the expression of the tested proteins in plant tissues; thus, the potential proteasomal degradation process obviously occurs already within the living tissues. We assay protein destabilization, however, only in the extracts, with the time zero sample serving as the initial reference point. Hence, we define it as a cell-free assay.

One important aspect for the success of this assay is the correct choice of the expression vector from which the tested protein(s) will be produced. Unless specific antibodies against the tested protein are available, it should be epitope-tagged for detection by western blotting. The tagged protein should be expressed from an Agrobacterium binary vector. Whereas many such vectors are available <sup>26</sup>, we suggest using vectors derived from our modular pSAT plasmid system <sup>24</sup>, which allows one-step insertion of expression cassettes into the pPZP-RCS2 binary

plasmids<sup>24-25</sup>. Another advantage of the pSAT system is that it allows expression of multiple genes from the same vector<sup>25</sup>, which is especially useful for experiments to assay several proteasomal substrates or to study the effects of interactors of the tested substrate; for example coexpression of the Agrobacterium VirD5 protein that interacts with the proteasomal substrate VirF results in VirF protection from proteasomal degradation<sup>22</sup>. Importantly, the expanding pSAT series of vector already includes vectors for epitope tagging<sup>27</sup>. Regardless of the chosen cloning strategy, the sequence encoding the epitope-tagged protein of interest should be introduced in a binary vector for subsequent expression in plant tissues. Because this assay uses transient expression, the binary vector does not have to contain selection markers for stable transformation, although their presence is not detrimental to the assay efficiency.

Although coexpression of several proteins of interest is best achieved using multigene expression vectors, but it can also be done by combining equivalent volumes of liquid cultures of two or three Agrobacterium strains, each of which carries a separate binary construct.

Another critical point is that, in many cases, the proteasomal degradation assay involves expression not only of the proteasomal substrate, but also of a component of the SCF pathway. For example, the experimental goal might be to test whether an F-box protein recognizes and targets for degradation a specific substrate. In this case, this epitope-tagged substrate should be coexpressed with the untagged F-box protein.

For more detailed analysis of the data, the extent of protein degradation can be easily quantified by measuring the relative intensity of the western signals using the latest ImageJ software (NIH)<sup>31</sup>. When performing such quantification, it is important not to over-develop the western blots to avoid signal saturation. Data quantification also requires that all samples are loaded on the SDS-polyacrylamide gel equally in respect to their protein content as protein degradation in this assay is detected by reduction in the intensity of the appropriate protein band. This is achieved by determination of the protein content of each cell extract and by subsequent verification of equal loading of each lane (see Step 3.1). Furthermore, that, in any given time-course experiment, all samples are derived from the same batch of extract helps to ensure equal loading.

The cell-free assay for proteasomal degradation is described here uses plants as an experimental system. However, the same experimental design could be used for any other organism. The assay also can be extended by further focusing on the SCF pathway. For example, the SCF-dependent mechanism of protein degradation can be demonstrated using a dominant-negative form of the SCF component CULLIN1 (CUL1<sup>DN</sup>). Specifically, a mutant of Arabidopsis CUL1 with deleted amino acid residues between positions 1 and 420 has been shown to interact with the Skp1/ASK1 component of the SCF complex, but not with RBX1, which represents the catalytic core of SCF<sup>22</sup>. Inhibition or reduction of substrate degradation following coexpression of CUL1<sup>DN</sup> indicates involvement of the SCF pathway.

Our assay utilizes proteins of interest expressed in plant tissues, in their natural environment. One alternative to this approach is to purify recombinant proteins, add

them to plant extracts, and follow their degradation by western analysis<sup>32</sup>. We do not recommend this tactic as methodology of choice because recombinant proteins do not always faithfully reflect the native biological properties; however, if expression in planta is not feasible, the use of recombinant proteins certainly represents a valuable alternative.

#### **ACKNOWLEDGMENT**

EGC is supported by the U-Mobility Postdoctoral Fellowship. The work in our laboratory is supported by grants from NIH, USDA/NIFA, NSF, BARD, and BSF to V.C.


#### DISCLOSURES


No conflicts of interest declared.

#### REFERENCES

- 1. Patton, E.E., Willems, A.R., & Tyers, M. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. *Trends Genet.* **14**, 236-243 (1998).
- 2. Deshaies, R.J. SCF and cullin/RING H2-based ubiquitin ligases. *Annu. Rev. Cell Biol.* **15**, 435-467 (1999).
- 3. Callis, J., & Vierstra, R.D. Protein degradation in signaling. *Curr. Opin. Plant Biol.* **3**, 381-386 (2000).
- 4. Hellmann, H. & Estelle, M. Plant development: regulation by protein degradation. *Science* **297**, 793-797 (2002).
- 5. Hershko, A. & Ciechanover, A.. The ubiquitin system. *Annu. Rev. Biochem.* **67**, 425-479 (1998).
- 6. Dharmasiri, S. & Estelle, M. The role of regulated protein degradation in auxin response. *Plant Mol. Biol.* **49**, 401-409 (2002).
- 7. Devoto, A., Muskett, P.R., & Shirasu, K. Role of ubiquitination in the regulation of plant defence against pathogens. *Curr. Opin. Plant Biol.* **6**, 307-311 (2003).
- 8. Itoh, H., Matsuoka, M., & Steber, C.M.. A role for the ubiquitin-26S-proteasome pathway in gibberellin signaling. *Trends Plant Sci.* **8**, 492-497 (2003).
- 9. Wang, T. The 26S proteasome system in the signaling pathways of TGF-beta superfamily. *Front. Biosci.* **8**, d1109-d1127 (2003).
- 10. Pagano, M. Control of DNA synthesis and mitosis by the Skp2- p27-Cdk1/2 axis. *Mol. Cell* **14**, 414-416 (2004).
- 11. Magori, S. & Citovsky, V. Hijacking of the host SCF ubiquitin ligase machinery by plant pathogens. *Front. Plant Sci.* **2**, 87 (2011).
- 12. Gelvin, S.B. Agrobacterium-mediated plant transformation: the biology behind the "gene-jockeying" tool. *Microbiol. Mol Biol. Rev.* **67**, 16-37 (2003).
- 13. Lacroix, B. & Citovsky, V. The roles of bacterial and host plant factors in Agrobacterium-mediated genetic transformation. *Int. J. Dev. Biol.* **57**, In press, (2013).
- 14. Schrammeijer, B., *et al.* Interaction of the virulence protein VirF of Agrobacterium tumefaciens with plant homologs of the yeast Skp1 protein. *Curr. Biol.* **11**, 258-262 (2001).
- 15. Zaltsman, A., Krichevsky, A., Loyter, A. & Citovsky, V. Agrobacterium induces expression of a plant host F-box protein required for tumorigenicity. *Cell Host Microbe* **7**, 197-209 (2010).

- 16. Tzfira, T., Vaidya, M. & Citovsky, V. Involvement of targeted proteolysis in plant genetic transformation by Agrobacterium. *Nature* **431**, 87-92 (2004).
- 17. Zaltsman, A., Lacroix, B., Gafni, Y. & Citovsky, V. Disassembly of synthetic Agrobacterium T-DNA-protein complexes via the host SCF<sup>VBF</sup> ubiquitin-ligase complex pathway. *Proc. Natl. Acad. Sci. USA* **110**, 169-174 (2013).
- 18. Zhou, P. & Howley, P.M. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. *Mol. Cell* **2**, 571-580 (1998).
- 19. Galan, J.M. & Peter, M. Ubiquitin-dependent degradation of multiple F-box proteins by an autocatalytic mechanism. *Proc. Natl. Acad. Sci. USA* **96**, 9124-9129 (1999).
- 20. Ayad, N.G., Rankin, S., Murakami, M., Jebanathirajah, J., Gygi, S. & Kirschner, M.W. Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC. *Cell* **113**, 101-113 (2003).
- 21. Guardavaccaro, D., et al. Control of meiotic and mitotic progression by the F box protein b-Trcp1 in vivo. *Dev. Cell* **4**, 799-812 (2003).
- 22. Magori, S. & Citovsky V. Agrobacterium counteracts host-induced degradation of its F-box protein effector. *Sci. Signal.* **4**, ra69 (2011).
- 23. Margottin-Goguet, F., Hsu, J.Y., Loktev, A., Hsieh, H.M., Reimann, J.D. & Jackson, P.K. Prophase destruction of Emi1 by the SCFbTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. *Dev. Cell* **4**, 813-826 (2003).
- 24. Tzfira, T., *et al.* pSAT vectors: a modular series of plasmids for fluorescent protein tagging and expression of multiple genes in plants. *Plant Mol. Biol.* **57**, 503-516 (2005).
- 25. Goderis, I.J., *et al.* A set of modular plant transformation vectors allowing flexible insertion of up to six expression units. *Plant Mol. Biol.* **50**, 17-27 (2002).
- 26. Lee, L.Y. & Gelvin, S.B. T-DNA binary vectors and systems. *Plant Physiol.* **146**, 325-332 (2008).
- 27. Dafny-Yelin, M. & Tzfira, T. Delivery of multiple transgenes to plant cells. *Plant Physiol.* **145**, 1118-1128 (2007).
- 28. Yang, P., *et al.* Purification of the Arabidopsis 26 S proteasome: biochemical and molecular analyses revealed the presence of multiple isoforms. *J. Biol. Chem.* **279**, 6401-6413 (2004).
- 29. Fenteany, G., et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science* **268**, 726-731 (1995).
- 30. Ausobel, F.M., *et al.* (eds.) Current Protocols in Molecular Biology. New York: Wiley-Interscience (1987).
- 31. Rasband, W.S. ImageJ. U.S. National Institutes of Health, Bethesda, Maryland, USA, imagej.nih.gov/ij, 1997-2013 (2013).
- 32. Kim, J.H. & Kim, W.T. The Arabidopsis RING E3 ubiquitin ligase AtAIRP3/LOG2 participates in positive regulation of high salt and drought stress responses. *Plant Physiol.* **162**, 1733-1749 (2013).





Name of Material/ Equipment	Company	<b>Catalog Number</b>	Comments/Description
Bio-Rad Protein Assay Kit	Bio-Rad	500-0001	
Proteinase Inhibitor Cocktail	Sigma-Aldrich	S8820	
Mini-Protean System	Bio-Rad	165-8000	
Semi-dry Western Blotting SD			
Electrotransfer System	Bio-Rad	170-3940	
Affinity Purified Rabbit Anti-HA			
Antibody	icllab	RHGT-45A-Z	
Goat Anti-Rabbit IgG Peroxidase			
Conjugate	Thermo Scientific	31460	
BioTrace, NT Nitrocellulose Transfer			
Membrane	Pall Corportation	27377-000	
Immobilon Western Chemiluminescent			
HRP Substrate	EMD Millipore	WBKL SO 050	
MG132	EMD Millipore	474790-1MG	
Lactacystin	Sigma-Aldrich	L6785	
Thermo Scientific Pierce Fast Western			
Blot Kit, ECL Substrate	Pierce	35055	

Name of Material/ Equipment	Company	<b>Catalog Number</b>	<b>Comments/Description</b>
Protein assay kit	Bio-Rad	500-0001	
Proteinase inhibitor cocktail	Sigma-Aldrich	S8820	
Mini-Protean system	Bio-Rad	165-8000	
Semi-dry western blotting SD			
electrotransfer system	Bio-Rad	170-3940	
Affinity Purified Rabbit Anti-Ha	icllab	RHGT-45A-Z	
Goat anti-Rabbit IgG Peroxidase			
Conjugate	Thermo Scientific	31460	
BioTrace, NT nitrocellulose transfer			
membrane	Pall Corportation	27377-000	
Immobilon western chemiluminescent			
HRP substrate	EMD Millipore	WBKL S0 050	
MG132	EMD Millipore	474790-1MG	
Lactacystin	Sigma-Aldrich	L6785	
Thermo Scientific Pierce Fast Western			
Blot Kit, ECL Substrate	Pierce	35055	



## ARTICLE AND VIDEO LICENSE AGREEMENT

Manuscript #:	
Title of Article:	
Author(s):	
	box): The Author elects to have the Materials be made available (as described at ove.com/publish) via: Standard Access Open Access
Item 2 (check one bo	x):
The Auth	or is NOT a United States government employee.
	hor is a United States government employee and the Materials were prepared in the or her duties as a United States government employee.
	nor is a United States government employee but the Materials were NOT prepared in the or her duties as a United States government employee.

#### **ARTICLE AND VIDEO LICENSE AGREEMENT**

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found http://creativecommons.org/licenses/by-ncat: nd/3.0/legalcode; "Derivative Work" means a work based upon the Materials or upon the Materials and other preexisting works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties,

incorporating all or any portion of the Article, and in which the Author may or may not appear.

- 2. <u>Background</u>. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.
- 3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article

# 17 Sellers Street Cambridge, MA 02139 tel. +1.617.945.9051 www.JoVE.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

as provided in, but subject to all limitations and requirements set forth in, the CRC License.

- 4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.
- 5. <u>Grant of Rights in Video Standard Access</u>. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.
- 6. Grant of Rights in Video Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.
- 7. <u>Government Employees</u>. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the

- scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.
- 8. <u>Likeness, Privacy, Personality</u>. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.
- 9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.
- 10. <u>JoVE Discretion</u>. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its



17 Sellers Street Cambridge, MA 02139 tel. +1.617.945.9051= www.JoVE.com

# ARTICLE AND VIDEO LICENSE AGREEMENT

employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

- 12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.
- 13. <u>Transfer, Governing Law.</u> This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions.

AUTHOR:		
Name:	Elena Garcia-Cano	
Department:	Biochemistry and Cell Bioloy	
Institution:	Stony Brook University	
Article Title:	Assaying Proteasomal degradation in a cell-free system in plants	
Signature:	Date: 06.10.2013	

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pfd on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 17 Sellers St / Cambridge, MA 02139

For questions, please email editorial@jove.com or call +1.617.945.9051.



#### Dr. Elena García-Cano

Department of Biochemistry and Cell Biology Stony Brook, NY 11794-5215

Tel: 631.632.1015 Fax: 631.632.8575

elena.garcia-cano@stonybrook.edu

August 13, 2013

Dr. Larissa Jarzylo, Science Editor JoVE 17 Sellers St. Cambridge, MA 02139

Dear Dr. Jarzylo:

Enclosed please find our revised manuscript "Assaying proteasomal degradation in a cell-free system in plants". The revision addresses all comments of the Editor and three reviewers as detailed in our specific point-by-point response and in a marked copy of the revised paper.

I hope that our revisions will meet the high publication standards of JoVE.

Sincerely yours,

Elena García-Cano, Ph. D. Marie Curie Scholar

## **Editorial comments**

1. Editorial Policies of PNAS in regard to Figure 1 adapted from our paper Zaltsman et al., *Proc. Natl. Acad. Sci. USA* **110**, 169-174 (2013):

"The right to permit others to use your original figures or tables published in PNAS for noncommercial and educational use (i.e., in a review article, in a book that is not for sale), provided that the original source is cited. Third parties need not ask PNAS for permission to use figures and tables for such use."

http://www.pnas.org/site/aboutpnas/authorfag.xhtml

"PNAS authors need not obtain permission for the following cases: (1) to use their original figures or tables in their future works".

http://www.pnas.org/site/aboutpnas/rightperm.xhtml

# **Reviewer 1**

The Figure was attributed correctly as requested and the relevant link to the PNAS editorial policies was included in our response to the Editor.

# Reviewer 2

- 1. The light regime for agroinoculated plants, which is identical to the growth conditions of untreated plants, was detailed in the revised paper.
- 2. The sentence in Discussion was corrected and the Figure legend was also corrected as suggested.

#### Reviewer 3

- 1. The reviewer is correct that at least part of the degradation process may occur in planta, before the extracts are made. But the assay monitors degradation only within the extract, upon its incubation, with the time zero serving as the initial reference point. Thus, strictly speaking, we assay that part of the process which occurs in the extract during the incubation. Proteasomal inhibitors indeed act in the plant, but the do so by inhibiting the proteasome, which is then unable to act in the extract. This point was clarified in the revised paper.
- 2. We added an online reference for a bead-beating procedure protocol and gave example of the required equipment.
- 3. The protease inhibitor cocktail mainly affects serine, cysteine, aspartic, and metalloproteases, and does not interfere with the 26S protease. This point was clarified in the revised paper.
- 4. We indeed use the Bradford protein assay. Our extensive experience shows that, because protein concentration of the sample is known, precise quantification of RuBisCo content or serial dilutions are not required; these would only complicate the assay. Furthermore, in any given time-course experiment, all samples are derived from the same batch of extract which inherently assures equal loading. Potential pipetting variations, which normally are not dramatic, are verified by comparing intensities of the RuBisCo band on stained gels or membranes. These points were clarified in the revised paper.
- 5. Immunoblotting is indeed a standard procedure; however, it does have many different variations in terms of blocking conditions, etc. Thus, we feel that the specific variation used in our lab warrants description as the entire assay depends on the correct blotting protocol.
- 6. In our experience, the NIH ImageJ software reliably quantifies ECL band intensity. Again, there is no need for serial dilutions of the western reactions.



#### **Dr. Vitaly Citovsky**

Department of Biochemistry and Cell Biology Stony Brook, NY 11794-5215

Tel: 631.632.9534 Fax: 631.632.8575

vitaly.citovsky@stonybrook.edu

July 15, 2013

Dr. Larissa Jarzylo, Science Editor *JoVE* 17 Sellers St. Cambridge, MA 02139

Dear Dr. Jarzylo:

Enclosed please find our revised manuscript "Assaying proteasomal degradation in a cell-free system in plants". The revision addresses all comments of the Editor as detailed in our specific point-by-point response and in a marked copy of the revised paper.

I hope that our revisions will meet the high publication standards of JoVE.

Sincerely yours,

Vitaly Citovsky,

Professor of Biochemistry and Cell Biology

## **Editorial comments**

- 1. All sections marked by the Editor in red have been re-written to avoid use of text from our previous publications. Sorry and thanks.
- 2. Protocol was completely re-written to focus on the specific procedures and imperative tense was used throughout this part of the paper.
- 3. Discussion was also re-written to include critical points and information for success of the assay, potential expansion of the assay, and its technical alternatives.